



BioLight Life Sciences Ltd.

(the "Company")

July 10, 2025

To: Israel Security Authority
www.isa.gov.il

TASE Tel Aviv Stock Exchange
www.tase.co.il

Re: Positive Final Results in Human Clinical Study for Evaluating Innovative Technology for Diagnosing Retinal Diseases

The Company is pleased to announce that on July 9, 2025, it received the final results of a human feasibility clinical study for the evaluation and assessment of an innovative technology for diagnosing retinal diseases using tears (the "Feasibility Clinical Study" and the "Technology").

The final results of the Feasibility Clinical Study indicate the Technology's ability to differentiate between various conditions and stages of Age-Related Macular Degeneration (AMD), a disease that affects approximately 200 million people worldwide and is the leading cause of blindness in the Western world.

These study results are based on findings of differential biological activity across the various stages of the disease, related to distinct biological activity signatures in a small subset of proteins (identified from a scan of approximately 10,000 proteins).

In the Company's assessment, the ability to assess retinal diseases in general, and AMD in particular, through analysis of tear fluid is highly innovative and has commercial potential both for diagnostic purposes and for the discovery and development of new drugs.

The final results of the Feasibility Clinical Study are based on 40 human tear samples collected from individuals at different stages or conditions of AMD (30 samples) and 10 control samples from healthy individuals.

The study was conducted at the Tel Aviv Sourasky Medical Center (Ichilov), and the enzymatic activity analysis of the tear samples was performed by Prof. Yifat Merbl,

currently at the Weizmann Institute of Science, and one of the inventors of the Technology, at the Harvard University in the United States.

In light of the positive feasibility study results, the Company intends to exercise its option with Harvard University to obtain an exclusive license to the Technology, under terms that include immaterial payments and future royalties based on sales, as is customary in such license agreements. The Company also plans to seek collaborations with commercial entities in the diagnostics and drug development fields and to raise funds for the development of products based on the Technology.

Forward-Looking Statement – The information, details, and assessments contained in this report regarding the potential of the clinical feasibility study and the Technology, the exercise of the option, potential collaborations resulting therefrom, and/or any other commercial potential and/or fundraising for development, including the conduct of clinical trials, constitute “forward-looking information” as defined in the Israeli Securities Law, 1968. Such information involves high uncertainty and is based, among other things, on third-party factors and numerous variables not necessarily under the Company’s control. Therefore, the information, details, and assessments described herein may not materialize at all, or may materialize only partially, or in a materially different manner than originally anticipated.

About the Company

The Company holds and invests in companies ("Portfolio Companies") in the field of eye diseases and treatments through investment, management, development, and commercialization of projects and technologies and/or products in the fields of advanced medical devices, drugs, diagnostics, and digital medicine in the eye field (together - "Eye Products"), which aim to address real needs in the field of eye diseases and treatments. The Portfolio Companies and their various Eye Products are at different developmental, clinical (or pre-clinical), and commercial stages, ranging from initial development to sales.

Sincerely,

BioLight Life Sciences Ltd.